Диабет 2-го типа у взрослых

National Institute for Health and Care Excellence. Diabetes in pregnancy: management from preconception to the postnatal period. December 2020 [internet publication].Полный текст

Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020 Jan 7;41(2):255-323.Полный текст  Аннотация

National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. November 2021 [internet publication].Полный текст

Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018 Dec;41(12):2669-701.Полный текст  Аннотация

Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018 – a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020 Feb;63(2):221-8.Полный текст  Аннотация

1. Meigs JB, Muller DC, Nathan DM, et al. The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging. Diabetes. 2003 Jun;52(6):1475-84.Полный текст  Аннотация

2. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016 Apr 6;387(10027):1513-30.Полный текст  Аннотация

3. Magliano DJ, Islam RM, Barr ELM, et al. Trends in incidence of total or type 2 diabetes: systematic review. BMJ. 2019 Sep 11;366:l5003.Полный текст  Аннотация

4. International Diabetes Federation. IDF diabetes atlas - 9th edition. 2019 [internet publication].Полный текст

5. Preis SR, Pencina MJ, Hwang SJ, et al. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation. 2009 Jul 6;120(3):212-20.Полный текст  Аннотация

6. Gregg EW, Zhuo X, Cheng YJ, et al. Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985-2011: a modelling study. Lancet Diabetes Endocrinol. 2014 Nov;2(11):867-74. Аннотация

7. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014 Mar 22;383(9922):1068-83.Полный текст  Аннотация

8. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol. 2006 Mar 21;47(6):1093-100.Полный текст  Аннотация

9. Wormser D, Kaptoge S, Di Angelantonio E, et al; Emerging Risk Factors Collaboration. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011 Mar 26;377(9771):1085-95.Полный текст  Аннотация

10. Mayer-Davis EJ, Lawrence JM, Dabelea D, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002-2012. N Engl J Med. 2017 Apr 13;376(15):1419-29.Полный текст  Аннотация

11. National Institute for Health and Care Excellence. Type 2 diabetes: prevention in people at high risk. September 2017 [internet publication].Полный текст

12. National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes in America. 3rd edition. Bethesda, MD: National Institutes of Health, NIH Pub No. 17-1468; 2018.Полный текст

13. Hemmingsen B, Gimenez-Perez G, Mauricio D, et al. Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017 Dec 4;(12):CD003054.Полный текст  Аннотация

14. Coustan DR, Carpenter MW, O'Sullivan PS, et al. Gestational diabetes: predictors of subsequent disordered glucose metabolism. Am J Obstet Gynecol. 1993 Apr;168(4):1139-44; discussion 1144-5. Аннотация

15. American Diabetes Association. Standards of medical care in diabetes - 2022. Diabetes Care. 2022 Jan 1;45(Suppl 1):S1-259.Полный текст

16. National Institute for Health and Care Excellence. Diabetes in pregnancy: management from preconception to the postnatal period. December 2020 [internet publication].Полный текст

17. Sattar N, Gill JM. Type 2 diabetes in migrant south Asians: mechanisms, mitigation, and management. Lancet Diabetes Endocrinol. 2015 Dec;3(12):1004-16. Аннотация

18. Ma RC, Chan JC. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci. 2013 Apr;1281:64-91.Полный текст  Аннотация

19. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care. 2011 Jun;34(6):1249-57.Полный текст  Аннотация

20. Shai I, Jiang R, Manson JE, et al. Ethnicity, obesity, and risk of type 2 diabetes in women: a 20-year follow-up study. Diabetes Care. 2006 Jul;29(7):1585-90.Полный текст  Аннотация

21. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020: estimates of diabetes and its burden in the United States. 2020 [internet publication].Полный текст

22. Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988-2012. JAMA. 2015 Sep 8;314(10):1021-9. Аннотация

23. Shan Z, Li Y, Zong G, et al. Rotating night shift work and adherence to unhealthy lifestyle in predicting risk of type 2 diabetes: results from two large US cohorts of female nurses. BMJ. 2018 Nov 21;363:k4641.Полный текст  Аннотация

24. Evert AB, Dennison M, Gardner CD, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care. 2019 May;42(5):731-54.Полный текст  Аннотация

25. LeBlanc EL, Patnode CD, Webber EM, et al; Agency for Healthcare Research and Quality (US). Behavioral and pharmacotherapy weight loss interventions to prevent obesity-related morbidity and mortality in adults: an updated systematic review for the U.S. Preventive Services Task Force. September 2018 [internet publication].Полный текст  Аннотация

26. NHS England. NHS diabetes prevention programme (NHS DPP) [internet publication].Полный текст

27. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403.Полный текст  Аннотация

28. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care. 1997 Apr;20(4):537-44. Аннотация

29. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001 May 3;344(18):1343-50.Полный текст  Аннотация

30. Knowler WC, Fowler SE, Hamman RF, et al; Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009 Nov 14;374(9702):1677-86. Аннотация

31. Balk EM, Earley A, Raman G, et al. Combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the Community Preventive Services Task Force. Ann Intern Med. 2015 Sep 15;163(6):437-51.Полный текст  Аннотация

32. Gerstein HC, Yusuf S, Bosch J, et al; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006 Sep 23;368(9541):1096-105.Полный текст  Аннотация

33. Apolzan JW, Venditti EM, Edelstein SL, et al. Long-term weight loss with metformin or lifestyle intervention in the Diabetes Prevention Program Outcomes Study. Ann Intern Med. 2019 May 21;170(10):682-90. Аннотация

34. Moelands SV, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database Syst Rev. 2018 Dec 28;(12):CD005061.Полный текст  Аннотация

35. Hemmingsen B, Sonne DP, Metzendorf MI, et al. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017;(5):CD012204.Полный текст  Аннотация

36. Roberts S, Barry E, Craig D, et al. Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes. BMJ Open. 2017 Nov 15;7(11):e017184.Полный текст  Аннотация

37. Haw JS, Galaviz KI, Straus AN, et al. Long-term sustainability of diabetes prevention approaches: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2017 Dec 1;177(12):1808-17. Аннотация

38. Herman WH, Pan Q, Edelstein SL, et al; Diabetes Prevention Program Research Group. Impact of lifestyle and metformin interventions on the risk of progression to diabetes and regression to normal glucose regulation in overweight or obese people with impaired glucose regulation. Diabetes Care. 2017 Dec;40(12):1668-77.Полный текст  Аннотация

39. Galaviz KI, Weber MB, Straus A, et al. Global diabetes prevention interventions: a systematic review and network meta-analysis of the real-world impact on incidence, weight, and glucose. Diabetes Care. 2018 Jul;41(7):1526-34.Полный текст  Аннотация

40. Armato JP, DeFronzo RA, Abdul-Ghani M, et al. Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES). Lancet Diabetes Endocrinol. 2018 Oct;6(10):781-9. Аннотация

41. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation. 2019 Sep 10;140(11):e596-e646.Полный текст  Аннотация

42. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020 Jan 7;41(2):255-323.Полный текст  Аннотация

43. Rosenzweig JL, Bakris GL, Berglund LF, et al. Primary prevention of ASCVD and T2DM in patients at metabolic risk: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019 Sep;104(9):3939-85.Полный текст  Аннотация

44. World Health Organization. Classification of diabetes mellitus. 2019 [internet publication].Полный текст

45. World Health Organization. Screening for type 2 diabetes: report of a World Health Organization and International Diabetes Federation meeting. 2003 [internet publication].Полный текст

46. Newton CA, Raskin P. Diabetic ketoacidosis in type 1 and type 2 diabetes mellitus: clinical and biochemical differences. Arch Intern Med. 2004 Sep 27;164(17):1925-31.Полный текст  Аннотация

47. Umpierrez GE, Kitabchi AE. Diabetic ketoacidosis: risk factors and management strategies. Treat Endocrinol. 2003;2(2):95-108. Аннотация

48. Puttanna A, Padinjakara RNK. Diabetic ketoacidosis in type 2 diabetes mellitus. Pract Diab. 2014;31(4):155-8.Полный текст

49. Medicines and Healthcare products Regulatory Agency. SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis. April 2016 [internet publication].Полный текст

50. National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management. July 2021 [internet publication].Полный текст

51. National Institute for Health and Care Excellence. 2019 surveillance of type 1 diabetes in adults: diagnosis and management (2015) NICE guideline NG17. 2019 [internet publication].Полный текст

52. Sacks DB, Arnold M, Bakris GL, et al; National Academy of Clinical Biochemistry. Position statement executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care. 2011 Jun;34(6):1419-23.Полный текст  Аннотация

53. Lampasona V, Petrone A, Tiberti C, et al. Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes: Non Insulin Requiring Autoimmune Diabetes (NIRAD) 4. Diabetes Care. 2010 Jan;33(1):104-8.Полный текст  Аннотация

54. Newman JD, Berger JS, Ladapo JA. Underuse of medications and lifestyle counseling to prevent cardiovascular disease in patients with diabetes. Diabetes Care. 2019 May;42(5):e75-e76.Полный текст  Аннотация

55. National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. November 2021 [internet publication].Полный текст

56. National Institute for Health and Care Excellence. Diabetic foot problems: prevention and management. October 2019 [internet publication].Полный текст

57. National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. August 2019 [internet publication].Полный текст

58. Strain WD, Hope SV, Green A, et al. Type 2 diabetes mellitus in older people: a brief statement of key principles of modern day management including the assessment of frailty – a national collaborative stakeholder initiative. Diabet Med. 2018 Jul;35(7):838-45.Полный текст  Аннотация

59. Sinclair A, Gallagher A. Managing frailty and associated comorbidities in older adults with diabetes: position statement on behalf of the Association of British Clinical Diabetologists (ABCD). 2019 [internet publication].Полный текст

60. Strain WD, Down S, Brown P, et al. Diabetes and frailty: an expert consensus statement on the management of older adults with type 2 diabetes. Diabetes Ther. 2021 May;12(5):1227-47.Полный текст  Аннотация

61. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004 Jul;88(4):787-835, ix. Аннотация

62. Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005 Sep;28(9):2289-304.Полный текст  Аннотация

63. National Institute for Health and Care Excellence. Chronic kidney disease: assessment and management. November 2021 [internet publication].Полный текст

64. National Institute for Health and Care Excellence. Peripheral arterial disease: diagnosis and management. December 2020 [internet publication].Полный текст

65. Anstee QM, McPherson S, Day CP. How big a problem is non-alcoholic fatty liver disease? BMJ. 2011 Jul 18;343:d3897. Аннотация

66. Norris JM, Johnson RK, Stene LC. Type 1 diabetes-early life origins and changing epidemiology. Lancet Diabetes Endocrinol. 2020 Mar;8(3):226-38.Полный текст  Аннотация

67. O'Neal KS, Johnson JL, Panak RL. Recognizing and appropriately treating latent autoimmune diabetes in adults. Diabetes Spectr. 2016 Nov;29(4):249-52.Полный текст  Аннотация

68. Naik RG, Brooks-Worrell BM, Palmer JP. Latent autoimmune diabetes in adults. J Clin Endocrinol Metab. 2009 Dec;94(12):4635-44.Полный текст  Аннотация

69. Pihoker C, Gilliam LK, Ellard S, et al; SEARCH for Diabetes in Youth Study Group. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth. J Clin Endocrinol Metab. 2013 Oct;98(10):4055-62.Полный текст  Аннотация

70. Fajans SS, Bell GI. MODY: history, genetics, pathophysiology, and clinical decision making. Diabetes Care. 2011 Aug;34(8):1878-84.Полный текст  Аннотация

71. Chiang JL, Maahs DM, Garvey KC, et al. Type 1 diabetes in children and adolescents: a position statement by the American Diabetes Association. Diabetes Care. 2018 Sep;41(9):2026-44.Полный текст  Аннотация

72. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med. 2001 Sep 27;345(13):971-80. Аннотация

73. Vellanki P, Umpierrez GE. Diabetic ketoacidosis: a common debut of diabetes among African Americans with type 2 diabetes. Endocr Pract. 2017 Aug;23(8):971-8.Полный текст  Аннотация

74. Steenkamp DW, Alexanian SM, Sternthal E. Approach to the patient with atypical diabetes. CMAJ. 2014 Jun 10;186(9):678-84.Полный текст  Аннотация

75. UK National Screening Committee. Adult screening programme: diabetes. November 2019 [internet publication].Полный текст

76. US Preventive Services Task Force. Prediabetes and type 2 diabetes: screening. August 2021 [internet publication].Полный текст

77. Sherifali D, Bai JW, Kenny M, et al. Diabetes self-management programmes in older adults: a systematic review and meta-analysis. Diabet Med. 2015 Nov;32(11):1404-14.Полный текст  Аннотация

78. Pillay J, Armstrong MJ, Butalia S, et al. Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis. Ann Intern Med. 2015 Dec 1;163(11):848-60.Полный текст  Аннотация

79. Chatterjee S, Davies MJ, Heller S, et al. Diabetes structured self-management education programmes: a narrative review and current innovations. Lancet Diabetes Endocrinol. 2018 Feb;6(2):130-42. Аннотация

80. Fisher L, Hessler D, Glasgow RE, et al. REDEEM: a pragmatic trial to reduce diabetes distress. Diabetes Care. 2013 Sep;36(9):2551-8.Полный текст  Аннотация

81. Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014 May;174(5):773-85. Аннотация

82. Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019 Apr 23;139(17):2022-31. Аннотация

83. Schnurr TM, Jakupović H, Carrasquilla GD, et al. Obesity, unfavourable lifestyle and genetic risk of type 2 diabetes: a case-cohort study. Diabetologia. 2020 Jul;63(7):1324-32.Полный текст  Аннотация

84. Blomster JI, Woodward M, Zoungas S, et al. The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial. BMJ Open. 2016 Jan 8;6(1):e009668.Полный текст  Аннотация

85. Hansen MB, Jensen ML, Carstensen B. Causes of death among diabetic patients in Denmark. Diabetologia. 2012 Feb;55(2):294-302. Аннотация

86. Tancredi M, Rosengren A, Svensson AM, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015 Oct 29;373(18):1720-32.Полный текст  Аннотация

87. Desai JR, Vazquez-Benitez G, Xu Z, et al. Who must we target now to minimize future cardiovascular events and total mortality? Lessons from the surveillance, prevention and management of diabetes mellitus (SUPREME-DM) cohort study. Circ Cardiovasc Qual Outcomes. 2015 Sep;8(5):508-16.Полный текст  Аннотация

88. Rawshani A, Rawshani A, Franzén S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018 Aug 16;379(7):633-44.Полный текст  Аннотация

89. Berkelmans GF, Gudbjörnsdottir S, Visseren FL, et al. Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with type 2 diabetes mellitus. Eur Heart J. 2019 Sep 7;40(34):2899-906. Аннотация

90. Diabetes UK. Position statement: low carb diets for people with diabetes. May 2021 [internet publication].Полный текст

91. Snorgaard O, Poulsen GM, Andersen HK, et al. Systematic review and meta-analysis of dietary carbohydrate restriction in patients with type 2 diabetes. BMJ Open Diabetes Res Care. 2017 Feb 23;5(1):e000354.Полный текст  Аннотация

92. Goldenberg JZ, Day A, Brinkworth GD, et al. Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: systematic review and meta-analysis of published and unpublished randomized trial data. BMJ. 2021 Jan 13;372:m4743.Полный текст  Аннотация

93. Prochaska JO, Velicer WF, Rossi JS, et al. Stages of change and decisional balance for 12 problem behaviors. Health Psychol. 1994 Jan;13(1):39-46. Аннотация

94. National Institute for Health and Care Excellence. Preventing excess weight gain. March 2015 [internet publication].Полный текст

95. National Institute for Health and Care Excellence. Weight management: lifestyle services for overweight or obese adults. May 2014 [internet publication].Полный текст

96. National Institute for Health and Care Excellence. Obesity: identification, assessment and management. November 2014 [internet publication].Полный текст

97. National Institute for Health and Care Excellence. Physical activity: brief advice for adults in primary care. May 2013 [internet publication].Полный текст

98. Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018 Feb 10;391(10120):541-51. Аннотация

99. Gregg EW, Chen H, Wagenknecht LE, et al; Look AHEAD Research Group. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA. 2012 Dec 19;308(23):2489-96.Полный текст  Аннотация

100. Lean ME, Leslie WS, Barnes AC, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019 May;7(5):344-55. Аннотация

101. Margolis KL, Asche SE, Bergdall AR, et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA. 2013 Jul 3;310(1):46-56.Полный текст  Аннотация

102. National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. September 2016 [internet publication].Полный текст

103. NHS England; NHS Accelerated Access Collaborative. Summary of national guidance for lipid management for primary and secondary prevention of CVD. 2021 [internet publication].Полный текст

104. Giugliano RP, Cannon CP, Blazing MA, et al; IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018 Apr 10;137(15):1571-82. Аннотация

105. Sabatine MS, Giugliano RP, Keech AC, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017 May 4;376(18):1713-22.Полный текст  Аннотация

106. Squizzato A, Suter MB, Nerone M, et al. PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis. Intern Emerg Med. 2017 Oct;12(7):1043-53. Аннотация

107. National Institute for Health and Care Excellence Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia. April 2021 [internet publication].Полный текст

108. National Institute for Health and Care Excellence. Stop smoking interventions and services. March 2018 [internet publication].Полный текст

109. National Institute for Health and Care Excellence. Smoking: harm reduction. July 2013 [internet publication].Полный текст

110. Rydén L, Grant PJ, Anker SD, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2013 Oct;34(39):3035-87.Полный текст  Аннотация

111. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.Полный текст  Аннотация

112. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts), developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016 Aug 1;37(29):2315-81.Полный текст  Аннотация

113. ASCEND Study Collaborative Group; Bowman L, Mafham M, Wallendszus K, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018 Oct 18;379(16):1529-39.Полный текст  Аннотация

114. Laiteerapong N, Cooper JM, Skandari MR, et al. Individualized glycemic control for US adults with type 2 diabetes: a cost-effectiveness analysis. Ann Intern Med. 2018 Feb 6;168(3):170-8. Аннотация

115. Ismail-Beigi F, Moghissi E, Tiktin M, et al. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011 Apr 19;154(8):554-9. Аннотация

116. National Institute for Health and Care Excellence. Hearing loss in adults: assessment and management. June 2018 [internet publication].Полный текст

117. Driver and Vehicle Licensing Agency. Information for drivers with diabetes. June 2021 [internet publication].Полный текст

118. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018 Dec;41(12):2669-701.Полный текст  Аннотация

119. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998 Sep 12;352(9131):854-65. Аннотация

120. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9;359(15):1577-89.Полный текст  Аннотация

121. Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia. 2017 Sep;60(9):1620-9.Полный текст  Аннотация

122. Gerstein HC, Miller ME, Genuth S, et al; ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011 Mar 3;364(9):818-28. Аннотация

123. Patel A, MacMahon S, et al; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 Jun 6;358(24):2560-72.Полный текст  Аннотация

124. Reaven PD, Emanuele NV, Wiitala WL, et al; VADT Investigators. Intensive glucose control in patients with type 2 diabetes - 15-year follow-up. N Engl J Med. 2019 Jun 6;380(23):2215-24.Полный текст  Аннотация

125. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 Jan 8;360(2):129-39.Полный текст  Аннотация

126. Gerstein HC, Miller ME, Byington RP, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2545-59.Полный текст  Аннотация

127. Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018 – a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020 Feb;63(2):221-8.Полный текст  Аннотация

128. Li S, Vandvik PO, Lytvyn L, et al. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. BMJ. 2021 May 11;373:n1091.Полный текст  Аннотация

129. National Institute for Health and Care Excellence. Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes. May 2016 [internet publication].Полный текст

130. National Institute for Health and Care Excellence. Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes. March 2019 [internet publication].Полный текст

131. Herrington WG, Frankel AH. UK Kidney Association clinical practice guideline: sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease. Oct 2021 [internet publication]. Полный текст

132. National Institute for Health and Care Excellence. Canagliflozin in combination therapy for treating type 2 diabetes. June 2014 [internet publication].Полный текст

133. National Institute for Health and Care Excellence. Dapagliflozin in combination therapy for treating type 2 diabetes. November 2106 [internet publication].Полный текст

134. National Institute for Health and Care Excellence. Empagliflozin in combination therapy for treating type 2 diabetes. March 2015 [internet publication].Полный текст

135. Birmingham, Solihull, Sandwell and Environs Area Prescribing Committee; Diabetes Medicines Management Advisory Group. Type 2 diabetes mellitus: guideline for the choice of oral and non-insulin antihyperglycaemic agents in adults. June 2019 [internet publication].Полный текст

136. National Institute for Health and Care Excellence. 2019 surveillance of diabetes (NICE guidelines NG17, NG18, NG19 and NG28). June 2019 [internet publication].Полный текст

137. Medicines and Healthcare products Regulatory Agency. Insulin combined with pioglitazone: risk of cardiac failure. December 2014 [internet publication].Полный текст

138. Medicines and Healthcare products Regulatory Agency. GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued. June 2019 [internet publication].Полный текст

139. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015 Jan;75(1):33-59. Аннотация

140. Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017 Aug 17;377(7):644-57.Полный текст  Аннотация

141. Cherney DZ, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017 Aug;5(8):610-21. Аннотация

142. Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation. 2019 Aug 27;140(9):739-50.Полный текст  Аннотация

143. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019 Jan 5;393(10166):31-39. Аннотация

144. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295-306.Полный текст  Аннотация

145. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28.Полный текст  Аннотация

146. Mahaffey KW, Neal B, Perkovic V, et al; CANVAS Program Collaborative Group. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018 Jan 23;137(4):323-34.Полный текст  Аннотация

147. Rådholm K, Figtree G, Perkovic V, et al. Canagliflozin and heart failure in type 2 diabetes mellitus. Circulation. 2018 Jul 31;138(5):458-68.Полный текст  Аннотация

148. Wiviott SD, Raz I, Bonaca MP, et al; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019 Jan 24;380(4):347-57.Полный текст  Аннотация

149. Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019 May 28;139(22):2528-36.Полный текст  Аннотация

150. Figtree GA, Rådholm K, Barrett TD, et al. Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus. Circulation. 2019 May 28;139(22):2591-3.Полный текст  Аннотация

151. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008.Полный текст  Аннотация

152. National Institute for Health and Care Excellence. Dapagliflozin for treating chronic heart failure with reduced ejection fraction. February 2021 [internet publication].Полный текст

153. Cinti F, Moffa S, Impronta F, et al. Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. Drug Des Devel Ther. 2017 Oct 3;11:2905-19.Полный текст  Аннотация

154. ClinicalTrials.gov. Cardiovascular outcomes following ertugliflozin treatment in type 2 diabetes mellitus participants with vascular disease: the VERTIS CV study (MK-8835-004). April 2019 [internet publication].Полный текст

155. ClinicalTrials.gov. Ertugliflozin trial in diabetes with preserved or reduced ejection fraction mechanistic evaluation in heart failure (ERADICATE-HF). May 2018 [internet publication].Полный текст

156. Htike ZZ, Zaccardi F, Papamargaritis D, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017 Apr;19(4):524-36. Аннотация

157. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007 Jul 11;298(2):194-206. Аннотация

158. Gerstein HC, Colhoun HM, Dagenais GR, et al; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019 Jul 13;394(10193):121-30. Аннотация

159. Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-44.Полный текст  Аннотация

160. Kaul S. Mitigating cardiovascular risk in type 2 diabetes with antidiabetes drugs: a review of principal cardiovascular outcome results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 trials. Diabetes Care. 2017 Jul;40(7):821-31.Полный текст  Аннотация

161. Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22.Полный текст  Аннотация

162. Hu Y. Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus. Chronic Dis Transl Med. 2019 Mar 15;5(1):25-36.Полный текст  Аннотация

163. Rosenstock J, Kahn SE, Johansen OE, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019 Sep 24;322(12):1155-66.Полный текст  Аннотация

164. US Food and Drug Administration. FDA drug safety communication: updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer. December 2016 [internet publication].Полный текст

165. European Medicines Agency. Questions and answers on the suspension of rosiglitazone-containing medicines (Avandia, Avandamet and Avaglim). September 2010 [internet publication].Полный текст

166. US Food and Drug Administration (FDA). FDA drug safety communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). June 2016 [internet publication].Полный текст

167. Ueda P, Svanström H, Melbye M, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018 Nov 14;363:k4365.Полный текст  Аннотация

168. Erondu N, Desai M, Ways K, et al. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015 Sep;38(9):1680-6.Полный текст  Аннотация

169. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015 Sep;38(9):1687-93.Полный текст  Аннотация

170. O'Keefe KL, Kemmeter PR, Kemmeter KD. Bariatric surgery outcomes in patients aged 65 years and older at an American Society for Metabolic and Bariatric Surgery Center of Excellence. Obes Surg. 2010 Sep;20(9):1199-205. Аннотация

171. European Medicines Agency. SGLT2 inhibitors: information on potential risk of toe amputation to be included in prescribing information. February 2017 [internet publication].Полный текст

172. Medicines and Healthcare products Regulatory Agency. SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes). March 2017 [internet publication].Полный текст

173. US Food and Drug Administration. FDA drug safety communication: FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. August 2018 [internet publication].Полный текст

174. Medicines and Healthcare products Regulatory Agency. SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum). February 2019 [internet publication].Полный текст

175. Tang H, Cui W, Li D, et al. Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017 Jan;19(1):142-7. Аннотация

176. Rosenstock J, Jelaska A, Zeller C, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015 Oct;17(10):936-48.Полный текст  Аннотация

177. Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014 Jul;37(7):1815-23.Полный текст  Аннотация

178. Wysham CH, Lin J, Kuritzky L. Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis. Postgrad Med. 2017 May;129(4):436-45. Аннотация

179. Maiorino MI, Chiodini P, Bellastella G, et al. Insulin and glucagon-like peptide 1 receptor agonist combination therapy in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care. 2017 Apr;40(4):614-24.Полный текст  Аннотация

180. Down S. How to advise on sick day rules. Diabetes Primary Care. 2020 Apr;22(3):47–8.Полный текст

181. Diabetes Canada. Clinical practice guidelines for the prevention and management of diabetes in Canada: appendix 8 - sick-day medication list. 2018 [internet publication].Полный текст

182. Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012 Aug 23;367(8):695-704.Полный текст  Аннотация

183. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012 Apr 26;366(17):1567-76.Полный текст  Аннотация

184. Schauer PR, Bhatt DL, Kirwan JP, et al; STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med. 2017;376:641-51.Полный текст  Аннотация

185. Kashyap SR, Bhatt DL, Wolski K, et al. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care. 2013 Aug;36(8):2175-82.Полный текст  Аннотация

186. Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA. 2013 Jun 5;309(21):2240-9.Полный текст  Аннотация

187. Halperin F, Ding SA, Simonson DC, et al. Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial. JAMA Surg. 2014 Jul;149(7):716-26.Полный текст  Аннотация

188. Yska JP, van Roon EN, de Boer A, et al. Remission of type 2 diabetes mellitus in patients after different types of bariatric surgery: a population-based cohort study in the United Kingdom. JAMA Surg. 2015 Dec;150(12):1126-33.Полный текст  Аннотация

189. Fisher DP, Johnson E, Haneuse S, et al. Association between bariatric surgery and macrovascular disease outcomes in patients with type 2 diabetes and severe obesity. JAMA. 2018 Oct 16;320(15):1570-82.Полный текст  Аннотация

190. O'Brien R, Johnson E, Haneuse S, et al. Microvascular outcomes in patients with diabetes after bariatric surgery versus usual care: a matched cohort study. Ann Intern Med. 2018 Sep 4;169(5):300-10. Аннотация

191. Park JY. Prediction of type 2 diabetes remission after bariatric or metabolic surgery. J Obes Metab Syndr. 2018 Dec 30;27(4):213-22.Полный текст  Аннотация

192. Tinker SC, Gilboa SM, Moore CA, et al. Specific birth defects in pregnancies of women with diabetes: National Birth Defects Prevention Study, 1997-2011. Am J Obstet Gynecol. 2020 Feb;222(2):176.e1-11.Полный текст  Аннотация

193. National Institute for Health and Care Excellence. Hypertension in pregnancy: diagnosis and management. June 2019 [internet publication].Полный текст

194. Raghavan S, Vassy JL, Ho YL, et al. Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults. J Am Heart Assoc. 2019 Feb 19;8(4):e011295.Полный текст  Аннотация

195. Harding JL, Pavkov ME, Magliano DJ, et al. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019 Jan 31;62(1):3-16.Полный текст  Аннотация

196. Ockrim Z, Yorston D. Managing diabetic retinopathy. BMJ. 2010 Oct 25;341:c5400. Аннотация

197. Thomas RL, Dunstan FD, Luzio SD, et al. Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service. Br J Ophthalmol. 2015 Jan;99(1):64-8. Аннотация

198. Centers for Disease Control (CDC). State-specific trends in chronic kidney failure - United States, 1990-2001. MMWR Morb Mortal Wkly Rep. 2004 Oct 8;53(39):918-20. Аннотация

199. Burrows NR, Hora I, Geiss LS, et al. Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes - United States and Puerto Rico, 2000-2014. MMWR Morb Mortal Wkly Rep. 2017 Nov 3;66(43):1165-70.Полный текст  Аннотация

200. Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America. This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019 Aug 13;140(7):e294-324.Полный текст  Аннотация

201. Nichols GA, Gullion CM, Koro CE, et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004 Aug;27(8):1879-84. Аннотация

202. Barrett-Connor EL, Cohn BA, Wingard DL, et al. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA. 1991 Feb 6;265(5):627-31. Аннотация

203. Simpson TC, Weldon JC, Worthington HV, et al. Treatment of periodontal disease for glycaemic control in people with diabetes mellitus. Cochrane Database Syst Rev. 2015 Nov 6;(11):CD004714.Полный текст  Аннотация

204. Bascones-Martinez A, Matesanz-Perez P, Escribano-Bermejo M, et al. Periodontal disease and diabetes: review of the literature. Med Oral Patol Oral Cir Bucal. 2011 Sep 1;16(6):e722-9.Полный текст  Аннотация

205. Pathak RD, Schroeder EB, Seaquist ER, et al. Severe hypoglycemia requiring medical intervention in a large cohort of adults with diabetes receiving care in U.S. integrated health care delivery systems: 2005-2011. Diabetes Care. 2016 Mar;39(3):363-70. Аннотация

206. Davis SN, Umpierrez GE. Diabetic ketoacidosis in type 2 diabetes mellitus - pathophysiology and clinical presentation. Nat Clin Pract Endocrinol Metab. 2007 Nov;3(11):730-1. Аннотация

207. Kitabchi AE, Umpierrez GE, Miles JM, et al. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009 Jul;32(7):1335-43.Полный текст  Аннотация

208. Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019 Nov;7(11):845-54. Аннотация

209. Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-85. Аннотация

210. Ruta LM, Magliano DJ, Lemesurier R, et al. Prevalence of diabetic retinopathy in type 2 diabetes in developing and developed countries. Diabet Med. 2013 Apr;30(4):387-98. Аннотация

211. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015 Sep 30;2:17.Полный текст  Аннотация

212. Yau JW, Rogers SL, Kawasaki R, et al; Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012 Mar;35(3):556-64.Полный текст  Аннотация

213. Hoffstad O, Mitra N, Walsh J, et al. Diabetes, lower-extremity amputation, and death. Diabetes Care. 2015 Oct;38(10):1852-7.Полный текст  Аннотация

214. Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017 Jan;40(1):136-54.Полный текст  Аннотация

215. Ang L, Jaiswal M, Martin C, et al. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep. 2014;14(9):528.Полный текст  Аннотация

216. Rustad JK, Musselman DL, Nemeroff CB. The relationship of depression and diabetes: pathophysiological and treatment implications. Psychoneuroendocrinology. 2011 Oct;36(9):1276-86. Аннотация

217. Ke C, Lau E, Shah BR, et al. Excess burden of mental Illness and hospitalization in young-onset type 2 diabetes: a population-based cohort study. Ann Intern Med. 2019 Feb 5;170(3):145-54. Аннотация

218. Pamidi S, Tasali E. Obstructive sleep apnea and type 2 diabetes: is there a link? Front Neurol. 2012 Aug 13;3:126.Полный текст  Аннотация

219. Shaw JE, Punjabi NM, Naughton MT, et al. The effect of treatment of obstructive sleep apnea on glycemic control in type 2 diabetes. Am J Respir Crit Care Med. 2016 Aug 15;194(4):486-92. Аннотация

220. Martínez-Cerón E, Barquiel B, Bezos AM, et al. Effect of continuous positive airway pressure on glycemic control in patients with obstructive sleep apnea and type 2 diabetes: a randomized clinical trial. Am J Respir Crit Care Med. 2016 Aug 15;194(4):476-85. Аннотация

221. Norris SL, Nichols PJ, Caspersen CJ, et al. Increasing diabetes self-management education in community settings: a systematic review. Am J Prev Med. 2002 May;22(suppl 4):39-66. Аннотация

222. Powers MA, Bardsley J, Cypress M, et al. Diabetes self-management education and support in type 2 diabetes: a joint position statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. Diabetes Care. 2015 Jul;38(7):1372-82.Полный текст  Аннотация

223. Young LA, Buse JB, Weaver MA, et al; Monitor Trial Group. Glucose self-monitoring in non-insulin-treated patients with type 2 diabetes in primary care settings: a randomized trial. JAMA Intern Med. 2017 Jul 1;177(7):920-9. Аннотация

224. Public Health England. Diabetic eye screening: programme overview. May 2021 [internet publication].Полный текст

225. Malanda UL, Welschen LM, Riphagen II, et al. Self monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. Cochrane Database Syst Rev. 2012 Jan 18;(1):CD005060.Полный текст  Аннотация

226. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003 Jan 30;348(5):383-93.Полный текст  Аннотация

227. Public Health England. Influenza: the green book, chapter 19. October 2020 [internet publication].Полный текст

228. Public Health England. Pneumococcal: the green book, chapter 25. January 2020 [internet publication].Полный текст